1. Home
  2. AXTA vs MDGL Comparison

AXTA vs MDGL Comparison

Compare AXTA & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Axalta Coating Systems Ltd.

AXTA

Axalta Coating Systems Ltd.

HOLD

Current Price

$29.17

Market Cap

5.9B

ML Signal

HOLD

Logo Madrigal Pharmaceuticals Inc.

MDGL

Madrigal Pharmaceuticals Inc.

HOLD

Current Price

$533.97

Market Cap

12.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AXTA
MDGL
Founded
1910
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Paints/Coatings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
12.2B
IPO Year
2014
2005

Fundamental Metrics

Financial Performance
Metric
AXTA
MDGL
Price
$29.17
$533.97
Analyst Decision
Buy
Strong Buy
Analyst Count
14
12
Target Price
$35.23
$674.45
AVG Volume (30 Days)
2.3M
351.2K
Earning Date
04-30-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
41.32
EPS
1.74
N/A
Revenue
$5,117,000,000.00
$180,133,000.00
Revenue This Year
$3.60
$58.39
Revenue Next Year
$3.26
$48.55
P/E Ratio
$17.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$24.94
$265.00
52 Week High
$35.72
$615.00

Technical Indicators

Market Signals
Indicator
AXTA
MDGL
Relative Strength Index (RSI) 52.86 61.03
Support Level $27.66 $503.93
Resistance Level $29.47 $539.17
Average True Range (ATR) 0.80 17.68
MACD 0.38 -0.85
Stochastic Oscillator 58.66 56.00

Price Performance

Historical Comparison
AXTA
MDGL

About AXTA Axalta Coating Systems Ltd.

Axalta Coating Systems Ltd is a manufacturer, marketer, and distributor of high-performance coatings systems. It operates in two segments: Performance Coatings and Mobility Coatings. The Performance Coatings segment provides liquid and powder coatings solutions to a fragmented and local customer base. Its end markets include refinish and industrial, and the Mobility Coatings segment relates to the provision of coating technologies to original equipment manufacturers of light and commercial vehicles. The majority of its revenue is generated from the Mobility Coatings segment. Geographically, the company generates maximum revenue from the Europe, Middle East and Africa (EMEA) region, followed by North America, Asia Pacific, and Latin America.

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

Share on Social Networks: